Incyte announced positive results from the Phase 3 COMFORT-II study evaluating ruxolitinib for the reduction in spleen size of patients with myelofibrosis. COMFORT-II (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy), a randomized, open-label study, enrolled 219 patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. Data showed that treatment with ruxolitinib provided a statistically significant reduction in spleen size of ≥35% from baseline to Week 48 as measured by MRI (or CT scan in applicable patients), when compared with best available therapy.
Ruxolitinib is an investigational Janus kinase (JAK) 1 and 2 inhibitor.
For more information call (302) 498.6700 or visit www.incyte.com.